To coincide with World Diabetes Day on 14 November, the first issue of MIMS Spotlight focussed on diabetes.
In recent months, NICE has updated its guidance on the management of type II diabetes, new hypoglycaemic agents including Onglyza (saxagliptin) have been launched, and experimental treatments such as dapagliflozin have shown promise in late-stage clinical trials.
By drawing together developments like these alongside a selection of quick-reference MIMS resources, MIMS Spotlight helps you:
- choose the right treatments
- follow national guidelines
- support and advise your patients
- keep abreast of emerging medicines.
The new bulletin is designed to complement the MIMS Product Update, which already provides MIMS users with a monthly email summary of new drugs and licence changes.
Topics to be covered in future editions of MIMS Spotlight include contraception, arthritis and asthma/COPD.
To sign up for MIMS Spotlight or MIMS Product Update, go to www.mims.co.uk/Bulletins/